Telesis Bio (NASDAQ:TBIO – Get Free Report) will likely be posting its resultson Thursday, August 6th. Analysts expect the company to post earnings of ($6.39) per share and revenue of $2.5330 million for the quarter.
Telesis Bio Price Performance
NASDAQ:TBIO opened at $0.00 on Thursday. Telesis Bio has a 52 week low of $0.00 and a 52 week high of $0.15. The company has a market capitalization of $1,982.20, a P/E ratio of -0.00 and a beta of 2.43. The stock’s fifty day moving average is $0.01 and its two-hundred day moving average is $0.04.
About Telesis Bio
Telesis Bio, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications.
The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants.
Read More
- Five stocks we like better than Telesis Bio
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
